FDA Grants AltruBio AbGn-168H (Neihulizumab) Orphan Drug Designation
2017
Feb
AltruBio was invited to the "World ADC Summit Berlin 2017" presented the progress of AltruBio’ ADCs, an antibody drug conjugate to treat cancer.
2016
Aug
AltruBio obtains FDA approval to conduct the Phase 1 clinical trial for AbGn-107 as a treatment for pancreatic, gastric and colorectal cancers.
Jan
AltruBio demonstrated the proof of initial efficacy in a Phase-2a clinical trial study of AbGn-168H in patients with psoriatic arthritis.
2015
Mar
The Phase 1b clinical trial for AbGn-168H in aGvHD received approval from the FDA and was led by Stanford Health Care.
Feb
AbGn-168H’s phase-II clinical trial targeting psoriasis completed in the United States.
2014
Nov
Phase-2a clinical trial for the use of AbGn-168H in treating psoriatic arthritis approved by the FDA and initiated.
May
Phase 2 clinical trial for AbGn-168H targeting psoriasis with increasing dose, initiate in the U.S.
Feb
Phase 2a clinical trial for AbGn-168H completed in the U.S.
2013
Dec
AltruBio developed AbGn-107, an antibody drug conjugate to treat cancer, and applied for a patent from the USPTO. AbGn-107 enriched the AltruBio’ pipeline and was a new drug for the global market.
2012
Aug
A Phase 2a clinical trial for AbGn-168H (targeting psoriasis) received approval from the FDA to initiate trial in the U.S.
2011
Nov
Boehringer Ingelheim completed the Phase 1 clinical trial study of AbGn-168H. A single dose intravenous injection was given to healthy male volunteers in Germany.
May
Boehringer Ingelheim was approved by the EU to conduct Phase 1 clinical trial of AbGn-168 to treat psoriasis. The trial used intravenous injection to deliver a single dose in healthy male volunteers.
2010
Oct
Boehringer Ingelheim was approved by the FDA to conduct further Phase 1 clinical trials of AbGn-168 to treat psoriasis. This trial tested an intravenous injection with a single dose and was conducted in the United States and Germany.
2008
Nov
Boehringer Ingelheim was approved by the FDA to conduct a Phase 1 clinical trial of AbGn-168 to treat psoriasis.
Feb
AltruBio Cooperatief U.A. founded AltruBio B.V. (AbGBV) in the Netherlands and founded AltruBio B.V. Taiwan Branch (AbGBVTW) to continue investments in R&D resources in Taiwan.
2007
Dec
AbGCV founded AltruBio Cooperatief U.A. (AbGCOOP) in the Netherlands to comply with the new drug licensing agreements in the European Union.
Nov
BioAlliance C.V. (AbGCV) established in the Netherlands by AbGUS in order to obtain international patents.
2006
Jun
AltruBio International Inc. (AbGUS) formed in the United States to exchange information and handle licensing negotiations as well as strategic cooperation between North American pharmaceutical and biotech companies.
2005
May
Boehringer Ingelheim and AltruBio corporation signed a license agreement for the “Therapeutic Monoclonal Antibody-168”.
2003
Jun
AltruBio developed a monoclonal antibody treatment for colorectal cancer--AbGn-7. Proof of efficacy established through animal testing. AltruBio filed a patent application with the USPTO.
2002
Jan
AltruBio developed AbGn-168, a monoclonal antibody treatment for multiple immune diseases and filed a patent application with the USPTO.
2001
Mar
AltruBio developed AbProtTM, AbScreenTM for DNA vaccines. The RNA molecules induce antibody immune responses.
